logo Standing Up To Powerful Interests

Safe & Affordable Prescription Drugs

 

What's New

Consumers, seniors and taxpayers won a big victory in January when the House of Representatives passed a bill to allow Medicare to negotiate bulk discounts with drugmakers. Price negotiations could save the program and taxpayers tens of billions of dollars.

Now it is time for the Senate to pass this common-sense legislation.



Overview

Pharmaceutical companies make important life-saving medicines. But that shouldn't give them license to drive up drug prices, ignore the risks of harmful side effects, or block needed reforms in Congress and the states. Consider:

- Pharmaceutical companies use direct-to-consumer ads to sell their latest, most expensive drugs. The industry claims that these ads help to educate consumers, but a WISPIRG analysis of FDA records for the years 2001-2005 found that the ads for 150 different drugs were false or misleading.

- Merck, the manufacturer of Vioxx, continued to market its painkiller to doctors and patients years after the company had substantial evidence of increased the risk of heart problems. FDA researchers estimate that, in less than 5 years, Vioxx may have caused as many as 139,000 heart attacks and strokes.

- The industry continues to use unscrupulous marketing techniques to influence prescriptions that doctors write, including fancy meals, travel junkets and money—in the form of “consultant” fees.

- More than 3 million seniors are falling into the doughnut hole—Medicare’s prescription drug coverage gap. Seniors have to keep paying their monthly premiums, but Medicare does not pay for their drugs until seniors pay $3,600 in out-of-pocket expenses for their medicines. When Congress created the Medicare prescription drug benefit, the pharmaceutical industry and its lobbyists inserted a provision that prohibits the program from negotiating bulk-rate discounts for drugs.

WISPIRG is working to require drug companies to fully disclose studies and information about the safety and effectiveness of their drugs, to enable the FDA to better crack down on misleading drug advertisements, to rein in inappropriate gifts to doctors, and to allow Congress to negotiate drug discounts for the Medicare program.




DECEPTIVE AD PULLED—The drug Paxil, intended to treat social anxiety disorder, made headlines for side effects like teen suicide and severe withdrawal symptoms. Drugmaker GlaxoSmithKline ran television ads that promised relief from shyness and self-consciousness, expanding the scope of the drug. The FDA later pulled the ad. (Source: FDA’s letter to GlaxoSmithKline)

 

SEARCH THIS SITE